+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07223944

Safety and Effectiveness Study of FLT201 Gene Therapy in Adults with Gaucher Disease Type 1

Led by Spur Therapeutics · Updated on 2026-10-14

45

Participants Needed

32

Research Sites

221 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of FLT201, a gene therapy, in adults with Gaucher disease Type 1 who have been on stable enzyme replacement or substrate reduction therapy for at least two years. This Phase 3 study aims to confirm how well FLT201 works and its safety after participants stop their current therapies. Participants will receive a single intravenous infusion of FLT201, which is an advanced gene therapy made from a modified virus vector carrying genetic material. The study is non-randomized and conducted at multiple centers, focusing on this one group receiving the investigational treatment. Throughout the study, participants will be monitored for response to FLT201 over a year to evaluate its effectiveness. Researchers will assess safety and track health outcomes, with the overall study lasting several years. This includes follow-up visits and evaluations to understand long-term impacts of the gene therapy.

CONDITIONS

Brief Title

A Gaucher Disease Gene Therapy Trial With FLT201

Research Team

S

Spur Clinical Trials Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here